Brain scan study aims to predict glioblastoma drug response

NCT ID NCT04566185

Completed Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed pilot study tested whether two types of brain scans—FDG PET and CT perfusion—can predict how well the drug bevacizumab works in people with recurrent glioblastoma, an aggressive brain cancer. Fourteen patients were scanned before treatment and then classified as responders or non-responders based on MRI results. The goal is to find a way to identify who will benefit from this therapy, avoiding unnecessary side effects for those who won't.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Bevacizumab (anti-angiogenic therapy)
What this could lead to: If successful, this could help doctors predict which patients with recurrent glioblastoma will respond to bevacizumab, enabling more personalized treatment decisions.
What could go wrong: This is a very small pilot study with only 14 participants, so results may not apply broadly. The scans are being tested as predictors, not as a proven treatment guide.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA

Contacts and locations

Locations

CHU de Nimes

Nîmes, 30029, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.